Advanced search
Publication Cover
Clinical Ophthalmology Volume 17, 2023 - Issue
Submit an article Journal homepage
299
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration

Neesurg Mehta1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USA
,
Rodney D Fong1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USA;2 University of Nevada, Reno School of Medicine, Reno, NV, USAORCID Iconhttps://orcid.org/0000-0001-9645-1049
ORCID Icon,
Machelle Wilson3 Department of Public Health Sciences, Division of Biostatistics, University of California, Davis, CA, USA
,
Kareem Moussa1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USA
,
Parisa Emami-Naeini1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USA;4 Department of Ophthalmology, Veterans Administration Hospital, Mather, CA, USA
,
Ala Moshiri1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USA
,
Glenn Yiu1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USAORCID Iconhttps://orcid.org/0000-0003-3061-3310
ORCID Icon &
Susanna S Park1 Department of Ophthalmology and Vision Science, University of California Davis Health, Sacramento, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5911-6671
ORCID Icon show all
Pages 657-665 | Received 01 Dec 2022, Accepted 09 Feb 2023, Published online: 27 Feb 2023

References

  • CDC. Common eye disorders and diseases; 2020. Available from: https://www.cdc.gov/visionhealth/basics/ced/index.html. Accessed October 14, 2020.
  • Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127:1–65. doi:10.1016/j.ophtha.2019.09.024
  • Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84. doi:10.1016/j.ophtha.2019.04.017
  • Novartis Pharmaceuticals Corporation. BEOVU- Brolucizumab Injection, Solution, [package insert]; 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d. Accessed February 13, 2023.
  • Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–1059. doi:10.1016/j.ophtha.2020.11.011
  • Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89–99. doi:10.1016/j.ophtha.2020.06.028
  • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201. doi:10.1016/j.ophtha.2013.08.011
  • Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.e5. doi:10.1016/j.ophtha.2008.10.018
  • Maguire MG, Martin DF, Ying G-S; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. 5-year outcomes with anti-VEGF treatment of neovascular Age-related Macular Degeneration (AMD): the comparison of AMD treatments trials. Ophthalmology. 2016;123:1751–1761. doi:10.1016/j.ophtha.2016.03.045
  • Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF. Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better. Clin Ophthalmol Auckl NZ. 2019;13:347–351. doi:10.2147/OPTH.S191170
  • Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299. doi:10.1016/j.ophtha.2013.03.046
  • Metrangolo C, Donati S, Mazzola M, et al. OCT biomarkers in neovascular age-related macular degeneration: a narrative review. J Ophthalmol. 2021;2021:9994098. doi:10.1155/2021/9994098
  • Bulirsch LM, Saßmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021;bjophthalmol-2020–318672. doi:10.1136/bjophthalmol-2020-318672
  • Avaylon J, Lee S, Gallemore RP. Case series on initial responses to intravitreal brolucizumab in patients with recalcitrant chronic wet age-related macular degeneration. Int Med Case Rep J. 2020;13:145–152. doi:10.2147/IMCRJ.S252260
  • Sharma A, Kumar N, Parachuri N, et al. Brolucizumab—early real-world experience: BREW study. Eye. 2021;35:1045–1047. doi:10.1038/s41433-020-1111-x
  • Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration – Indian real-world experience: the BRAILLE Study. Clin Ophthalmol. 2021;15:3787–3795. doi:10.2147/OPTH.S328160
  • Jain A, Chea S, Matsumiya W, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. doi:10.1016/j.ajoc.2020.100687
  • Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. doi:10.1016/j.ajoc.2020.100680
  • Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4:269–279. doi:10.1177/2474126420930863
  • Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127:1345–1359. doi:10.1016/j.ophtha.2020.04.017
  • Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and Komodo healthcare map. JAMA Ophthalmol. 2022;140:20–28. doi:10.1001/jamaophthalmol.2021.4585

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.